Nasdaq

Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...
Business Insider

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)

HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies ...
Business Wire

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...
Morningstar

METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and ...
Nasdaq

Channel Therapeutics Corporation Reports Positive Results from Pre-Clinical Trials of Non-Opioid Nerve Block Formulations for Acute Pain Treatment

Channel Therapeutics announced successful pre-clinical results for its non-opioid pain treatment formulations, outperforming bupivacaine in efficacy and duration. Channel Therapeutics Corporation has ...
PharmTech

The Impact of Patient-Centric Formulations on Service Providers

PharmTech spoke with Dr. Asma Patel, VP Global Commercial and Scientific Consulting–Drug Product, to find out how the growth ...
Ophthalmology Times

Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases

Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and ...
Business Wire

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
The Manila Times

Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...
Seeking Alpha

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback The Company expects to disclose topline data from its ...